FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases FDA OKs Second Etanercept Biosimilar for Inflammatory Diseases

Etanercept-ykro (Eticovo) is approved across all eligible indications for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.FDA Approvals
Source: Medscape Rheumatology Headlines - Category: Rheumatology Tags: Rheumatology News Alert Source Type: news